RxDoctor Payments DataLook up a doctor →

James North, MD

Pain Medicine · Winston Salem, NCNPI 1780638163

Payments from drug & device makers

$3,710,030in general payments, 2019–2025

Across 1,810 payments — averaging $2049.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2.5M
  • Averitas Pharma Inc.$322K
  • Vertex$211K
  • Zynex Medical, Inc.$160K
  • GRT US Holding, Inc.$154K
  • Arthrex$135K
  • plus $251K from 36 others
$73,260in research payments, 2019–2025

Across 8 payments — averaging $9157.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$55K
  • MDD US Operations, LLC$18K

What the payments were for

  • Consulting fees$117,18016%
  • Speaking & faculty fees$404,74456%
  • Travel & lodging$131,54218%
  • Food & beverage$22,5303%
  • Education$44,8956%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,710,030 in reported general payments places this provider in the 95th percentile of 182 pain medicine providers in North Carolina.

See all pain medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$666,446
Medicare patients
699
Services billed
18,859

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
QutenzaCapsaicin/Skin Cleanser16$55,875
NucyntaTapentadol Hcl12$21,254
Xtampza ErOxycodone Myristate14$11,006
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen205$5,906
Buprenorphine21$5,286
Naloxone Hcl60$3,874
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen108$3,066
Oxycodone Hcl65$1,394
Gabapentin72$1,164
Morphine Sulfate ErMorphine Sulfate28$1,156
Pregabalin42$880
Tizanidine Hcl37$652
Hydromorphone Hcl35$630
Celecoxib44$421
Tramadol Hcl38$410

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GRT US Holding, Inc.Qutenza$154,433$55,87516 claims
Collegium Pharmaceutical, Inc.Nucynta, Xtampza Er$176$32,25926 claims
Hikma Pharmaceuticals USABuprenorphine$48$5,28621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 182 pain medicine providers in North Carolina.

Other pain medicine in Winston Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →